Cancer Clinical Trial
Official title:
Effects of Two Different Yoga Interventions on the Quality of Life of Breast Cancer Patients Compared With Waiting List - a Three-arm Randomized Controlled Trial
NCT number | NCT05327543 |
Other study ID # | YOMA |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 9, 2022 |
Est. completion date | December 2024 |
Verified date | August 2023 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Study investigates the effects of two different yoga interventions on the health-related quality of life in breast cancer patients. Qualitative and quantitative data will be collected.
Status | Recruiting |
Enrollment | 138 |
Est. completion date | December 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Histologically confirmed diagnosis of non-metastatic breast cancer (TNM stage I-III) up to 5 years after diagnosis - Primary therapy completed for at least 3 months - Limitation of the quality of life due to the cancer (indication of at least 4 out of 10 points on the numerical analogue scale) - Willingness to participate in the study and signed informed consent. Exclusion Criteria: - Current or planned chemotherapy, radiation or surgery - Severe physical or psychopharmacologically treated psychiatric comorbidity due to which a patient is unable to participate in the study - Pregnancy/breastfeeding - Participation in other clinical trials with behavioral, psychological, or complementary medicine interventions - Immobility or limitation for gymnastic exercise due to orthopedic, neurologic, or other medical cause - regular meditation practice >2x/month - regular yoga practice >2x/month |
Country | Name | City | State |
---|---|---|---|
Germany | Charite University | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Qualitative interviews | Qualitative assessment will be carried out in qualitative interviews in 20 patients participating in the study. The interviews will be recorded, transcribed and analyzed with qualitative content analysis. | 8 weeks after inclusion | |
Other | Heart Rate Variability (HRV) | 24h measuring by Faros 180 | Date of inclusion (baseline), after 8 weeks | |
Primary | Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) | Assessing full scale, range 0-40, higher score meaning a better outcome | Date of inclusion (baseline), after 8 weeks | |
Secondary | Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) | Assessing full scale, range 0-40, higher score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Functional Assessment of Cancer Therapy: Fatigue (FACIT-F) | Assessing full scale, range 0-52, higher score meaning a better outcom | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Perceived Stress Scale (PSS-10) | Assessing full scale, range 0-40, lower score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Flourishing Scale (FS-D) | Assessing full scale, range 8-56, higher score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Self-Compassion Scale (SCS-D) | Mean score of 12 items, range 1-5, higher score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Self-Efficacy Scale (ASKU) | Mean score of 3 items, range 1-5, higher score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Sociodemographic measures | Age, education level, personal income, household income, employment status, job description, marital status, household members, days of sick leave past 3 months | Date of inclusion (baseline) | |
Secondary | Behavioral questions: cigarettes | Number of cigarettes on average per day in the last month | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Behavioral questions: alcohol | Number of alcoholic beverages on average per week in the last month | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Expectation question | expectation of effectiveness of the intervention on a 5-point likert scale, how they expect to handle the intervention on a 5-point likert scale, higher score meaning better outcome | Date of inclusion (baseline) | |
Secondary | Behavioural question | diet | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Behavioural question 2 | Practice of other mindfulness practices besides Yoga | Date of inclusion (baseline) | |
Secondary | Behavioural question 3 | Yoga styles were practiced before | Date of inclusion (baseline) | |
Secondary | Behavioural question 4 | If and how often yoga is practiced regularly | Date of inclusion (baseline) | |
Secondary | Functional Assessment of Cancer Therapy - General (FACT-G) | Assessing full scale, range 0-108, higher score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Yama/Niyama Questionnaire - YaNiQ | Assessing full scale, range 0-100, higher score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | Assessing full scale, range 0-42, lower score meaning a better outcome | Date of inclusion (baseline), after 8 weeks, after 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|